GDF Traps and EPO Activators for Red Blood Cell Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current erythropoietin (EPO) treatments for anemia are often ineffective, particularly in patients with cancer, end-stage renal disease, and myelodysplastic syndrome, and may be associated with adverse effects such as increased cardiovascular morbidity and tumor growth, necessitating the development of alternative methods to increase red blood cell levels with reduced EPO doses.
Innovation Solution
The use of GDF Traps in combination with EPO receptor activators to synergistically increase red blood cell formation, allowing for lower doses of EPO receptor activators and potentially reducing adverse effects, involves variant ActRIIB polypeptides with altered ligand-binding domains that preferentially antagonize activin and myostatin, thereby enhancing erythropoiesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If EPO receptor activators are used to increase red blood cell levels, then red blood cell formation is improved, but adverse effects such as cardiovascular morbidity and tumor growth increase
Solution Approach 1:
The patent introduces GDF traps as intermediary molecules that indirectly enhance red blood cell formation by blocking GDF11 and other activin-related ligands, rather than directly activating EPO receptors. This intermediary approach achieves the desired erythropoietic effect while avoiding the harmful overstimulation of EPO pathways that leads to cardiovascular morbidity and tumor growth.
Solution Approach 2:
The patent changes the mechanism parameter from direct EPO receptor activation to indirect activation via GDF trap-mediated blocking of negative regulators. This parameter change allows red blood cell formation to be enhanced through a different biological pathway that does not carry the same adverse effects associated with high-dose EPO therapy.
2Productivity
If high doses of EPO receptor activators are used to achieve target red blood cell levels, then red blood cell formation is improved, but adverse effects increase
Solution Approach 1:
GDF traps serve as mediators that amplify the erythropoietic response indirectly by blocking inhibitory signals (GDF11, activin ligands). This intermediary mechanism achieves equivalent or superior red blood cell formation to high-dose EPO therapy but without the need for high EPO doses, thereby reducing adverse effects.
Solution Approach 2:
Instead of applying full-dose EPO therapy which causes adverse effects, the patent uses GDF traps to partially block negative regulatory pathways, creating a cumulative erythropoietic effect that achieves target red blood cell levels with less overall stimulation and fewer side effects.
3Productivity
If EPO treatments are used for anemia, then red blood cell levels are increased, but effectiveness is reduced in patients with cancer, end-stage renal disease, and myelodysplastic syndrome
Solution Approach 1:
The patent uses GDF traps as intermediaries that work through a different biological mechanism (blocking GDF11 and activin ligands) rather than direct EPO receptor activation. This alternative pathway may bypass the resistance mechanisms present in cancer, end-stage renal disease, and myelodysplastic syndrome patients, improving treatment reliability in these difficult-to-treat populations.
Solution Approach 2:
The patent changes the therapeutic parameter from direct EPO pathway activation to indirect activation via GDF trap-mediated blocking of negative regulators. This parameter change may overcome treatment resistance in patients with cancer, end-stage renal disease, and myelodysplastic syndrome by engaging a different biological pathway that is less susceptible to the resistance mechanisms that limit EPO effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination therapy significantly increases red blood cell and hemoglobin levels, enabling target levels to be attained with lower EPO doses, thereby minimizing adverse effects and improving treatment outcomes for anemia-related disorders.
Implementation Method 1
GDF Traps are variant ActRIIB polypeptides with altered ligand-binding domains that preferentially antagonize activin and myostatin
Implementation Method 2
The use of GDF Traps in combination with EPO receptor activators to synergistically increase red blood cell formation
Data Source
AI summary
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.